Antibody Response to an mRNA SARS-CoV-2 Vaccine Following Initial Vaccination With Ad.26.COV2.S in Solid Organ Transplant Recipients: A Case Series.

Authors:: Chang A
Alejo JL
Abedon AT
Mitchell J
Chiang TP
Boyarsky BJ
Avery RK
Tobian AAR
Levan ML
Warren DS
Massie AB
Garonzik-Wang JM
Segev DL
Werbel WA
Source:: Transplantation [Transplantation] 2022 Feb 01; Vol. 106 (2), pp. e161-e162.
Publication Date:: 2022-02-01
Language:: English
Abstract:: Competing Interests: Dr Segev has the following financial disclosures: consulting and speaking honoraria from Sanofi, Novartis, CLS Behring, Jazz Pharmaceuticals, Veloxis, Mallinckrodt, and Thermo Fisher Scientific. Dr Avery has study/grant support from Aicuris, Astellas, Chimerix, Merck, Oxford Immunotec, Qiagen, Regeneron, Takeda/Shire, and Vir/GSK, and is an associate editor for Transplantation. Dr Levan is the Social Media Editor for Transplantation. The other authors declare no conflicts of interest.
Subjects:: Adult
Aged
Female
Humans
Male
Middle Aged
RNA, Messenger genetics
SARS-CoV-2 genetics
SARS-CoV-2 isolation purification
Vaccination adverse effects
Antibody Formation
COVID-19 prevention control
COVID-19 Vaccines administration dosage
Organ Transplantation adverse effects
Transplant Recipients
Format:: Report
DOI:: 10.1097/TP.0000000000003991
Database:: MEDLINE
Journal:: Transplantation
Volume:: 106
Issue:: 2
Page Start:: e161
ISSN:: 1534-6080

About this article